Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]fluoropropyl-trimethoprim is a radiolabeled small molecule diagnostic agent used for positron emission tomography (PET) imaging of bacterial infections. It is based on the antibiotic trimethoprim, which selectively inhibits bacterial dihydrofolate reductase (DHFR), an enzyme essential for DNA synthesis in bacteria. The fluorine-18 label enables sensitive and specific detection of live bacterial infections in vivo, distinguishing them from sterile inflammation or cancer. This agent demonstrates high uptake in live bacteria such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, with low background signal in non-infected tissues. Developed primarily by the University of Pennsylvania, it is being investigated as a tool for noninvasive diagnosis and localization of bacterial infections using PET/CT imaging[1][2][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]fluoropropyl-trimethoprim.